Andorra Approves Public Funding for Five High-Cost Complex Medications
CASS to fully cover treatments for cystinuria, candidiasis, biliary cholangitis, Parkinson's, plus expanded omalizumab access for allergies amid rising medical demands.
Key Points
- Andorra's CASS to fully fund five high-cost drugs: tiopronin for cystinuria, anidulafungin for candidiasis, seladelpar for biliary cholangitis, foslevodopa/foscarbidopa for Parkinson's.
- Annual costs range from 9,555 to over 69,000 euros per patient.
- Omalizumab access expanded to allergology specialists for severe allergies.
- Changes adapt public health system to medical advances and rising demands.
The Andorran government has approved changes to the regulations on public funding for high-complexity medications, enabling the Caixa Andorrana de Seguretat Social (CASS) to cover five new treatments at 100%.
These include tiopronin for severe homozygous cystinuria—a hereditary recessive condition affecting urine processing—anidulafungin for invasive candidiasis in cases of severe systemic fungal infections, seladelpar for primary biliary cholangitis, and foslevodopa/foscarbidopa for advanced Parkinson's disease. Annual costs for these therapies vary from 9,555 euros to over 69,000 euros, based on the drug and each patient's therapeutic needs.
The updated rules also allow allergology specialists to prescribe omalizumab, previously limited to pulmonology, paediatrics, dermatology, and internal medicine. This biologic targets severe persistent allergic asthma and chronic spontaneous urticaria, conditions that significantly affect patient well-being.
The changes form part of periodic reviews to adapt the public health system to medical progress and emerging care demands. Authorities aim to provide fair access to these expensive, specialised options for serious infections, chronic illnesses, rare disorders, and liver conditions.
This step reinforces the commitment of Andorran officials and CASS to embed cutting-edge therapies within the public healthcare system.
Original Sources
This article was aggregated from the following Catalan-language sources:
- Diari d'Andorra•
La CASS finançarà cinc nous medicaments d’alta complexitat al 100%
- Diari d'Andorra•
La CASS finançarà cinc nous medicaments d’alta complexitat al 100%
- La Veu Lliure•
Andorra incorpora cinc tractaments innovadors contra Parkinson, infeccions greus i malalties rares
- Altaveu•
Finançament del 100% de la CASS per a cinc nous tractaments d'alta complexitat
- El Periòdic•
La CASS finançarà cinc nous tractaments mèdics d’alta complexitat incorporats al reglament sanitari